Crowe HAF assisted Odyssée Venture in its acquisition
of a stake in Datexim as part of a €1.5 million
fundraising campaign.
Founded in 2011 and specialized in the treatment and
analysis of medical imaging, Datexim has developed a
cervical cancer screening solution based on artificial
intelligence.
After eight years of R&D, Datexim wishes to conquer
the market in France and Europe.